ACES Diagnostics: Funding Rounds, Investors & CEO

About ACES Diagnostics

Aces Diagnostics is developing LymeSeek for physicians and clinical laboratories. The single blood test combines proprietary biomarkers with machine learning to detect Lyme disease across its stages.

LymeSeek has shown more than 90% accuracy and has been tested on more than 700 clinical samples. Aces plans clinical trials and FDA review before a commercial launch in 2027.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
Oct 22, 2026	Oct 27, 2026	$7,082,529of $8.7M target	30	$236K	Equity, Series A-1, A-2 and A-3 Preferred Stock and the securities issued upon conversion of the Series A-1, A-2 and A-3 Preferred Stock.Rule 506(b)	Form D ↗
May 5, 2026	Jun 25, 2026	$400,000of $3.0M target	2	$200K	Debt, Unsecured Promissory Notes and the Securities into which Such Notes May ConvertRule 506(b)	Form D ↗
Jun 12, 2024	Oct 3, 2024amended Jun 25, 2026	$3,600,000fully sold	27	$133K	Debt, Unsecured Promissory Notes and the Securities into which such Notes May ConvertRule 506(b)	Form D/A ↗1 earlier filing
Total, three offerings		$11,082,529

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Why Investors Backed ACES Diagnostics

Aces is trying to close the period when Lyme disease symptoms appear but standard blood tests can still miss the infection. LymeSeek combines several antibody signals in one test and uses a machine-learning algorithm to interpret them. The company has moved the assay into clinical-trial and regulatory work. Bay Area Lyme Ventures supports that path from research to clinical use.

The problem it targets

Lyme disease can be difficult to confirm in the first weeks after infection. Aces's case is that standard two-tier tests often miss early cases, which can delay treatment. The company is building LymeSeek to give clinicians one result from a single blood draw during that uncertain period.

What the product does

LymeSeek is a multiplexed blood test that measures antibody responses to eight Borrelia burgdorferi antigens. A machine-learning algorithm converts the response pattern into a detected or not-detected result. The test is designed to run on equipment already used by clinical laboratories.

Progress so far

An October 2026 company release described a 467-sample training and validation cohort with 90% sensitivity and 93% specificity. A separate 50-patient evaluation detected 90% of cases within two weeks and all cases within 15 to 30 days. A transferred version tested on more than 250 people produced 90% sensitivity and 98% specificity.

Who backs it

Bay Area Lyme Ventures lists Aces among its initial portfolio companies. The venture-philanthropy fund says it supports products moving from Lyme disease research into clinical development and commercialization. Aces has not publicly named the amount of that investment.

We wrote this summary from public statements by ACES Diagnostics and its investors. It is not investment advice.